

# Eric P Winer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6615708/publications.pdf>

Version: 2024-02-01

209  
papers

36,347  
citations

8159

76  
h-index

3476

182  
g-index

212  
all docs

212  
docs citations

212  
times ranked

34018  
citing authors

#	ARTICLE	IF	CITATIONS
1	Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2. <i>Leukemia</i> , 2022, 36, 210-220.	3.3	12
2	Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 117-124.	0.4	11
3	The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1258-1267.	3.2	31
4	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 282-293.	0.8	88
5	CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1323-1334.	0.8	62
6	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 438-448.	0.8	35
7	Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1493-1499.	3.2	22
8	Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?. <i>Annals of Oncology</i> , 2022, 33, 234-238.	0.6	11
9	Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2- breast cancer. <i>Cancer Research</i> , 2022, 82, GS2-01-GS2-01.	0.4	2
10	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. <i>Npj Breast Cancer</i> , 2022, 8, 18.	2.3	8
11	Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 942-950.	13.9	220
12	Temporal and spatial topography of cell proliferation in cancer. <i>Nature Cell Biology</i> , 2022, 24, 316-326.	4.6	34
13	p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases. <i>Nature Communications</i> , 2022, 13, 1473.	5.8	10
14	The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II-III and metastatic breast cancers. <i>Breast Cancer Research and Treatment</i> , 2022, 194, 65-78.	1.1	10
15	A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 63.	2.3	18
16	STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	68
17	Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 2408-2419.	0.8	42
18	Breast Medical Oncologists' Perspectives of Telemedicine for Breast Cancer Care: A Survey Study. <i>JCO Oncology Practice</i> , 2022, 18, e1447-e1453.	1.4	3

#	ARTICLE	IF	CITATIONS
19	Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. <i>JCO Precision Oncology</i> , 2022, , .	1.5	11
20	Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 215-227.	1.1	10
21	CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. <i>Nature Cancer</i> , 2021, 2, 34-48.	5.7	48
22	Genomic Characterization of <i>de novo</i> Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1105-1118.	3.2	24
23	Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 983-991.	3.2	29
24	The Global Landscape of Treatment Standards for Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1143-1155.	3.0	13
25	Atezolizumab and <i>nab</i> -Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1005-1016.	3.0	171
26	Abstract PD14-04: Contribution of tumor and immune cells to PD-L1 as a predictive biomarker in triple-negative breast cancer (TNBC): Analysis from KEYNOTE-119. , 2021, , .		3
27	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 212-222.	5.1	169
28	Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 499-511.	5.1	260
29	Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 609.	3.4	15
30	Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab025.	1.4	8
31	The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2-positive breast cancer. <i>JCI Insight</i> , 2021, 6, .	2.3	20
32	Temporal and spatial topography of cell proliferation in cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3122-3122.	0.8	0
33	Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. <i>Cancer Discovery</i> , 2021, 11, 2474-2487.	7.7	92
34	Expanding Criteria for Prognostic Stage IA in Hormone Receptorâ€“Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1744-1750.	3.0	7
35	Saci-IO TNBC: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1â€“ metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS1106-TPS1106.	0.8	9
36	Saci-IO HR+: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1+ hormone receptor-positive (HR+) / HER2- metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS1102-TPS1102.	0.8	3

#	ARTICLE	IF	CITATIONS
37	ALEXANDRA/Impassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer.. Journal of Clinical Oncology, 2021, 39, TPS597-TPS597.	0.8	11
38	Survival in male breast cancer (MaBC) over the past three decades.. Journal of Clinical Oncology, 2021, 39, 569-569.	0.8	0
39	Genomic features of rapid versus late relapse in triple negative breast cancer. BMC Cancer, 2021, 21, 568.	1.1	10
40	PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer. Journal of the National Cancer Institute, 2021, 113, 1733-1743.	3.0	83
41	Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. Npj Breast Cancer, 2021, 7, 98.	2.3	4
42	Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. Journal of Clinical Oncology, 2021, 39, 2247-2256.	0.8	22
43	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. Journal of Clinical Oncology, 2021, 39, 2375-2385.	0.8	76
44	Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. Journal of Clinical Oncology, 2021, 39, 2720-2731.	0.8	52
45	Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. Npj Breast Cancer, 2021, 7, 110.	2.3	20
46	A Phase 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 111, 45-52.	0.4	5
47	Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nature Communications, 2021, 12, 5563.	5.8	19
48	Reply to M. Tanaka et al. Journal of Clinical Oncology, 2021, 39, JCO.21.01967.	0.8	0
49	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Annals of Oncology, 2021, 32, 1216-1235.	0.6	354
50	Weathering the Storm: Managing Older Adults With Breast Cancer Amid COVID-19 and Beyond. Journal of the National Cancer Institute, 2021, 113, 355-359.	3.0	10
51	Perceptions of patients with early stage breast cancer toward research biopsies. Cancer, 2021, 127, 1208-1219.	2.0	3
52	Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer. JCO Precision Oncology, 2021, 5, 1777-1787.	1.5	5
53	A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Research and Treatment, 2020, 179, 113-123.	1.1	26
54	Adjuvant Chemotherapy for Older Patients With Breast Cancer: When Is the Pain Worth the Gain?. Journal of the National Cancer Institute, 2020, 112, 551-552.	3.0	3

#	ARTICLE	IF	CITATIONS
55	Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. <i>Clinical Breast Cancer</i> , 2020, 20, 145-151.e2.	1.1	21
56	Aggressive Subsets of Metastatic Triple Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, e20-e26.	1.1	5
57	De-escalating Breast Cancer Surgery—Where Is the Tipping Point?. <i>JAMA Oncology</i> , 2020, 6, 183.	3.4	15
58	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 597-609.	13.9	789
59	Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 44-59.	5.1	826
60	Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 4120-4129.	0.8	32
61	A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor—Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6149-6157.	3.2	29
62	Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 4184-4193.	0.8	74
63	A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 238-245.	1.1	44
64	Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 120.	2.2	60
65	Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5974-5989.	3.2	87
66	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. <i>Journal of Clinical Oncology</i> , 2020, 38, 4274-4282.	0.8	276
67	Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor—Positive, ERBB2—Negative Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1598.	3.4	84
68	Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial. <i>Cancer Prevention Research</i> , 2020, 13, 1055-1062.	0.7	17
69	The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor—Positive Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 1174-1193.	7.7	176
70	Barriers to Clinical Trial Accrual: Perspectives of Community-Based Providers. <i>Clinical Breast Cancer</i> , 2020, 20, 395-401.e3.	1.1	7
71	Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2556-2564.	3.2	109
72	Randomized Phase II Trial of Exercise, Metformin, or Both on Metabolic Biomarkers in Colorectal and Breast Cancer Survivors. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz096.	1.4	14

#	ARTICLE	IF	CITATIONS
73	The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 2145-2156.	1.6	2
74	Tumor Mutational Burden and <i>PTEN</i> Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2565-2572.	3.2	138
75	De-Escalating Breast Cancer Surgery for Low-Risk Ductal Carcinoma in Situ—Reply. <i>JAMA Oncology</i> , 2020, 6, 1118.	3.4	3
76	Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC). <i>Cancer Research</i> , 2020, 80, PD5-03-PD5-03.	0.4	34
77	TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1002-1002.	0.8	35
78	Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1005-1005.	0.8	8
79	Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1013-1013.	0.8	42
80	A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1046-1046.	0.8	16
81	Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 500-500.	0.8	20
82	ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.. <i>Journal of Clinical Oncology</i> , 2020, 38, 504-504.	0.8	30
83	Response to neoadjuvant chemotherapy and the 21-gene breast recurrence score in young women with estrogen receptor-positive early breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 514-514.	0.8	0
84	Genomic profiling of breast cancer brain metastases reveals targetable alterations.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2525-2525.	0.8	0
85	Expanding criteria for prognostic stage IA disease in HR+ breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 550-550.	0.8	0
86	ABC trial (A011502): A randomized phase III double-blinded placebo-controlled trial of aspirin as adjuvant therapy breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS600-TPS600.	0.8	1
87	Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. <i>Breast Cancer Research</i> , 2019, 21, 78.	2.2	141
88	Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade. <i>Oncologist</i> , 2019, 24, e441-e449.	1.9	36
89	Breast Cancer Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 288.	3.8	2,785
90	Breast Cancer Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 316.	3.8	115

#	ARTICLE	IF	CITATIONS
91	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). <i>Clinical Cancer Research</i> , 2019, 25, 2975-2987.	3.2	76
92	Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. <i>Clinical Breast Cancer</i> , 2019, 19, 399-404.	1.1	27
93	The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 4644-4655.	3.2	76
94	Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). <i>Breast Cancer Research and Treatment</i> , 2019, 176, 303-310.	1.1	30
95	TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 714-722.	0.8	36
96	Olaparib and $\pm$ -specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. <i>Lancet Oncology</i> , The, 2019, 20, 570-580.	5.1	191
97	Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2019, 37, 423-438.	0.8	384
98	Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor -Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1868-1875.	0.8	229
99	Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses <sup>TM</sup> Health Studies. <i>Journal of the National Cancer Institute</i> , 2019, 111, 700-708.	3.0	44
100	Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies. <i>Nature Genetics</i> , 2019, 51, 207-216.	9.4	170
101	IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1003-1003.	0.8	59
102	Breast cancer-specific survival by age: Worse outcomes for the oldest patients. <i>Cancer</i> , 2018, 124, 2184-2191.	2.0	46
103	Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. <i>Cancer Cell</i> , 2018, 33, 173-186.e5.	7.7	201
104	Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?. <i>Clinical Cancer Research</i> , 2018, 24, 1795-1804.	3.2	67
105	Adjuvant Chemotherapy for ER+ Breast Cancer: A Sea Change is Underway. <i>Journal of the National Cancer Institute</i> , 2018, 110, 443-445.	3.0	1
106	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor -Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2804-2807.	0.8	93
107	Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 543-553.	0.8	162
108	Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2108-2121.	13.9	3,097

#	ARTICLE	IF	CITATIONS
109	Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 884-890.	0.8	365
110	A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 109.	2.2	48
111	Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5292-5304.	3.2	73
112	CDK4/6 inhibition in breast cancer: current practice and future directions. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878645.	1.4	218
113	Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 10.	2.3	95
114	Predicting breast cancer therapeutic response. <i>Nature Medicine</i> , 2018, 24, 535-537.	15.2	6
115	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 122-137.	13.9	448
116	Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative). <i>Journal of the American College of Surgeons</i> , 2017, 224, 688-694.	0.2	8
117	Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). <i>Journal of Clinical Oncology</i> , 2017, 35, 1061-1069.	0.8	254
118	Surveillance Mammography in Older Patients With Breast Cancer—Can We Ever Stop?. <i>JAMA Oncology</i> , 2017, 3, 402.	3.4	27
119	18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. <i>Clinical Cancer Research</i> , 2017, 23, 3053-3060.	3.2	66
120	T-DM1—an important agent in the history of breast cancer management. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 651-652.	12.5	6
121	CDK4/6 inhibition triggers anti-tumour immunity. <i>Nature</i> , 2017, 548, 471-475.	13.7	998
122	Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 316-324.	2.3	3
123	Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. <i>Nature Communications</i> , 2017, 8, 1324.	5.8	584
124	Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5687-5695.	3.2	170
125	Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. <i>Oncologist</i> , 2017, 22, 25-32.	1.9	79
126	Reply to S. Sorscher. <i>Journal of Clinical Oncology</i> , 2017, 35, 1746-1747.	0.8	0



#	ARTICLE	IF	CITATIONS
127	Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.. Journal of Clinical Oncology, 2017, 35, 1008-1008.	0.8	99
128	Phase 2 study of pembrolizumab as first-line therapy for PD-L1â€‘positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.. Journal of Clinical Oncology, 2017, 35, 1088-1088.	0.8	55
129	Randomized trial of a physical activity intervention in women with metastatic breast cancer. Cancer, 2016, 122, 1169-1177.	2.0	87
130	I-SPY 2 â€” Toward More Rapid Progress in Breast Cancer Treatment. New England Journal of Medicine, 2016, 375, 83-84.	13.9	47
131	PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). Npj Breast Cancer, 2016, 2, .	2.3	80
132	Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptorâ€‘Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). Journal of Clinical Oncology, 2016, 34, 2602-2609.	0.8	101
133	Perils of the Pathologic Complete Response. Journal of Clinical Oncology, 2016, 34, 3959-3962.	0.8	35
134	Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study. Breast Cancer Research and Treatment, 2016, 160, 305-312.	1.1	37
135	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. New England Journal of Medicine, 2016, 375, 1738-1748.	13.9	1,390
136	Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival. Journal of Clinical Oncology, 2016, 34, 3308-3314.	0.8	297
137	Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study. Breast, 2016, 30, 136-140.	0.9	4
138	Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage IIâ€‘III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Breast Cancer Research and Treatment, 2016, 160, 297-304.	1.1	63
139	Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. New England Journal of Medicine, 2016, 375, 209-219.	13.9	507
140	Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nature Medicine, 2016, 22, 723-726.	15.2	105
141	The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expressionâ€‘Based Meta-Analysis. Clinical Cancer Research, 2016, 22, 6039-6050.	3.2	48
142	Timeliness in Breast Cancer Treatmentâ€‘The Sooner, the Better. JAMA Oncology, 2016, 2, 302.	3.4	16
143	Adjuvant Endocrine Therapy for Women With Hormone Receptorâ€‘Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. Journal of Clinical Oncology, 2016, 34, 1689-1701.	0.8	243
144	Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2â€‘Positive Breast Cancer and Brain Metastases. Journal of Clinical Oncology, 2016, 34, 945-952.	0.8	148

#	ARTICLE	IF	CITATIONS
145	Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3764-3773.	3.2	733
146	Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1460-1468.	0.8	413
147	Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. <i>Cancer Cell</i> , 2016, 29, 255-269.	7.7	356
148	Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to Preoperative Trastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3249-3259.	3.2	88
149	Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. <i>Nature</i> , 2016, 529, 413-417.	13.7	490
150	Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 29.	3.4	68
151	Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. <i>Journal of Clinical Oncology</i> , 2016, 34, 542-549.	0.8	336
152	Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer. <i>Oncologist</i> , 2015, 20, 992-1000.	1.9	8
153	SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	30
154	Surgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast. <i>Annals of Surgical Oncology</i> , 2015, 22, 4280-4286.	0.7	15
155	Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 134-141.	13.9	598
156	Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 701-708.	0.8	171
157	Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women. <i>Oncologist</i> , 2015, 20, 713-718.	1.9	19
158	Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2772-2779.	0.8	141
159	Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study. <i>Cancer</i> , 2015, 121, 1937-1948.	2.0	8
160	Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). <i>Journal of Clinical Oncology</i> , 2015, 33, 2623-2631.	0.8	49
161	Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 2361-2369.	0.8	197
162	Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. <i>Journal of Clinical Oncology</i> , 2015, 33, 2254-2261.	0.8	232

#	ARTICLE	IF	CITATIONS
163	Acute appendicitis secondary to metastatic carcinoma of the breast: Case report and review of the literature. <i>Cancer Treatment Communications</i> , 2015, 4, 41-45.	0.4	2
164	Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 3809-3815.	0.7	81
165	TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1902-1909.	0.8	351
166	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , 2015, 5, 1164-1177.	7.7	821
167	Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	52
168	Phase II study of tivantinib (ARO 197) in patients with metastatic triple-negative breast cancer. <i>Investigational New Drugs</i> , 2015, 33, 1108-1114.	1.2	44
169	Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer. <i>Breast</i> , 2015, 24, S132-S135.	0.9	26
170	Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 13-21.	0.8	782
171	Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3840-3847.	0.8	253
172	Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. <i>Journal of Clinical Oncology</i> , 2014, 32, 3744-3752.	0.8	771
173	Comorbidity, Chemotherapy Toxicity, and Outcomes Among Older Women Receiving Adjuvant Chemotherapy for Breast Cancer on a Clinical Trial: CALGB 49907 and CALGB 361004 (Alliance). <i>Journal of Oncology Practice</i> , 2014, 10, e285-e292.	2.5	65
174	Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer- CALGB 40302 (Alliance). <i>Journal of Clinical Oncology</i> , 2014, 32, 3959-3966.	0.8	77
175	Frailty and Adherence to Adjuvant Hormonal Therapy in Older Women With Breast Cancer: CALGB Protocol 369901. <i>Journal of Clinical Oncology</i> , 2014, 32, 2318-2327.	0.8	80
176	Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2014, 32, 2255-2269.	0.8	661
177	Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. <i>Lancet Oncology</i> , The, 2014, 15, 1207-1214.	5.1	523
178	Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 2142-2150.	0.8	207
179	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 2100-2108.	0.8	165
180	Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500. <i>Journal of Clinical Oncology</i> , 2014, 32, 3483-3489.	0.8	543

#	ARTICLE	IF	CITATIONS
181	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 2078-2099.	0.8	303
182	Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 107-118.	13.9	621
183	Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance). <i>Journal of Clinical Oncology</i> , 2014, 32, 2311-2317.	0.8	70
184	Extended Therapy With Letrozole and Ovarian Suppression in Premenopausal Patients With Breast Cancer After Tamoxifen. <i>Clinical Breast Cancer</i> , 2014, 14, 413-416.	1.1	16
185	Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343. <i>Journal of Clinical Oncology</i> , 2013, 31, 2382-2387.	0.8	998
186	A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901. <i>Journal of Geriatric Oncology</i> , 2013, 4, 353-361.	0.5	11
187	Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101. <i>Journal of Clinical Oncology</i> , 2012, 30, 4071-4076.	0.8	76
188	A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine. <i>Journal of Clinical Oncology</i> , 2012, 30, 3234-3241.	0.8	319
189	Clinicopathologic features, patterns of recurrence, and survival among women with tripleâ€“negative breast cancer in the National Comprehensive Cancer Network. <i>Cancer</i> , 2012, 118, 5463-5472.	2.0	469
190	A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 1057-1065.	1.1	183
191	Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1145-1153.	0.8	860
192	Heterogeneity of breast cancer and implications of adjuvant chemotherapy. <i>Breast Cancer</i> , 2008, 15, 31-34.	1.3	24
193	Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. <i>Cancer</i> , 2008, 112, 700-709.	2.0	43
194	The optimal duration of adjuvant hormonal therapy for early-stage breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 573-4.	0.3	0
195	Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience. <i>Journal of Clinical Oncology</i> , 2007, 25, 3699-3704.	0.8	282
196	Case 32-2007. <i>New England Journal of Medicine</i> , 2007, 357, 1640-1648.	13.9	2
197	Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy. <i>Cancer</i> , 2005, 104, 1580-1589.	2.0	34
198	Adjuvant Chemotherapy in Older and Younger Women With Lymph Nodeâ€“Positive Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 1073.	3.8	371

#	ARTICLE	IF	CITATIONS
199	Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer. <i>New England Journal of Medicine</i> , 2004, 351, 971-977.	13.9	958
200	Clinical Evaluation of Once-Weekly Dosing of Epoetin Alfa in Chemotherapy Patients: Improvements in Hemoglobin and Quality of Life Are Similar to Three-Times-Weekly Dosing. <i>Journal of Clinical Oncology</i> , 2001, 19, 2875-2882.	0.8	574
201	Quality of Life Issues Among Women Undergoing High-Dose Chemotherapy for Breast Cancer. <i>Breast Disease</i> , 2001, 14, 41-50.	0.4	12
202	Phase II Evaluation of Thalidomide in Patients With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 2710-2717.	0.8	108
203	Is Axillary Lymph Node Dissection Indicated for Early-Stage Breast Cancer? A Decision Analysis. <i>Journal of Clinical Oncology</i> , 1999, 17, 1465-1465.	0.8	41
204	Inability to escalate vinorelbine dose intensity using a daily $\tilde{A}$ - 3 schedule with and without filgrastim in patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 68-72.	1.1	3
205	Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support. , 1999, 8, 167-176.		29
206	Complications of axillary lymph node dissection for carcinoma of the breast. <i>Cancer</i> , 1998, 83, 1362-1368.	2.0	221
207	Informed Consent for BRCA1 and BRCA2 Testing. <i>Breast Disease</i> , 1998, 10, 99-114.	0.4	11
208	Pharmacokinetics and clinical impact of all- trans retinoic acid in metastatic breast cancer: a phase II trial. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 40, 335-341.	1.1	55
209	Quality-of-life research in patients with breast cancer. <i>Cancer</i> , 1994, 74, 410-415.	2.0	27